Pembrolizumab plus enfortumab vedotin for bladder cancer

EV/Pembro and New Treatment Options for Metastatic Bladder CancerПодробнее

ASCO 2024: Game-Changing GU Oncology Updates w/ Dr. Monte Pal & Dr. Petros Grivas | URO Ep. 178Подробнее

EV-302/KEYNOTE-A39:Enfortumab Vedotin+Pembrolizumab vs. Chemotherapy in Metastatic Urothelial CancerПодробнее

Managing toxicities in advanced urothelial cancers: insights on EV and erdafitinibПодробнее

Enfortumab vedotin and pembrolizumab vs platinum-based combination therapies for patients with mUCПодробнее

FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for Bladder CancerПодробнее

Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles, MDПодробнее

Breakthrough in Bladder Cancer: FDA approval - Enfortumab Vedotin + Pelbrolizumab with Dr.Tom PowlesПодробнее

5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trialПодробнее

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancerПодробнее

EV-302: 1L enfortumab vedotin in combination with pembrolizumabПодробнее

The role of enfortumab vedotin in earlier lines and stages of urothelial cancer | Arjun BalarПодробнее

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or ...Подробнее

Dr. Rosenberg on Enfortumab Vedotin/Pembrolizumab in Urothelial CarcinomaПодробнее

Enfortumab vedotin plus pembrolizumab for advanced urothelial carcinomaПодробнее

Bladder: enfortumab vedotin + pembrolizumab & VESPER trialПодробнее

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metast...Подробнее

Ongoing clinical trials in bladder cancerПодробнее

EV-103: enfortumab vedotin and pembrolizumab in urothelial carcinomaПодробнее